Background
Heart failure, death, HF
HEART FAILURE, HEART, EMA
Heart failure (HF) is a prominent cause of morbidity and death, as well as a major financial burden on healthcare systems worldwide [HF remains a significant source of morbidity and mortality despite various therapies aimed at neurohumoral blocking. Sacubitril/Valsartan is a novel combination drug containing an angiotensin receptor blocker (ARB) (Valsartan) and a neprilysin inhibitor (Sacubitril) (ARNI) approved by the US food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with HF with reduced ejection fraction (HFrEF) [The American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC), according to this study, recently revised evidence-based recommendations for the management of HF [Since there is a scarcity of local evidence regarding safety and tolerability of using ARNI in HFrEF patients. Therefore, this study was conducted with an aim of to assess the safety and tolerability of Sacubitril/Valsartan, over a period of 12 weeks, in HFrEF patients coming to a tertiary care public sector hospital located in Karachi.